Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease
O. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea), Y. Koh (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), Y. Oh (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), C. Lim (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), J. Huh (Seoul, Republic of Korea), S. Hong (Seoul, Republic of Korea), T. Shim (Seoul, Republic of Korea), K. Jo (Seoul, Republic of Korea)
Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria
Disease area: Respiratory infections
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea), Y. Koh (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), Y. Oh (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), C. Lim (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), J. Huh (Seoul, Republic of Korea), S. Hong (Seoul, Republic of Korea), T. Shim (Seoul, Republic of Korea), K. Jo (Seoul, Republic of Korea). Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease. 538
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: